Substance P and other neuropeptides released after brain injury create a feedback loop that amplifies inflammation, suggesting both neurogenic and classical inflammatory pathways must be targeted for effective treatment.
Dual inflammatory pathway identifiedNeurogenic inflammation via substance P amplifies classical inflammation through a positive feedback loop, and both must be inhibited for effective TBI treatment
What the researchers found
TRP channels (TRPV1 and TRPA1) are activated by mechanical forces during brain injury, causing the release of substance P. This neuropeptide then drives multiple inflammatory processes: activating microglia and astrocytes, degranulating mast cells, promoting immune cell migration into the brain, and critically, increasing blood-brain barrier permeability through caveolae-mediated transcellular transport. This neurogenic inflammation creates a positive feedback loop with classical inflammation — bradykinin and prostaglandins from classical pathways further stimulate TRP channels, perpetuating neuropeptide release and escalating damage.
Why it matters
Clinical trials targeting inflammation after traumatic brain injury have repeatedly failed. This review proposes a compelling explanation: treatments have only addressed classical inflammation while ignoring the neurogenic component driven by substance P and other neuropeptides. If the neurogenic pathway is indeed a key initiating event, targeting it — or targeting both pathways simultaneously — could lead to the first effective anti-inflammatory therapies for brain injury.
How the study worked
This is a narrative review that synthesizes existing evidence from molecular, cellular, and preclinical studies on neurogenic inflammation following traumatic brain injury. The authors integrate findings on TRP channel activation, substance P signaling, blood-brain barrier permeability changes, and glial cell activation to propose a unified model of neuroinflammatory amplification.
What this study cannot tell us
This is a review paper synthesizing existing evidence, not presenting new experimental data. The proposed model of neurogenic-classical inflammatory feedback has not been directly validated in a single comprehensive study. Clinical evidence for targeting both pathways simultaneously in TBI patients does not yet exist. The relative contributions of neurogenic versus classical inflammation may vary by injury type and severity.
How to read the evidence
This is a narrative review article that synthesizes existing preclinical and mechanistic evidence into a proposed model. While it provides a compelling framework, it does not present new experimental data and the dual-pathway hypothesis requires clinical validation.
When this study was published
Published in 2016, this review remains highly relevant as TBI treatment trials continue to struggle. The neurogenic inflammation framework it proposes is still being actively investigated.
The bigger picture
Traumatic brain injury affects millions worldwide and remains without effective pharmacological treatment for secondary damage. The repeated failure of anti-inflammatory drugs in TBI clinical trials has been a major puzzle. This review reframes the problem by showing that neurogenic inflammation — driven by neuropeptides — may be the missing piece. The concept extends beyond TBI, as neurogenic inflammation is increasingly recognized in migraine, arthritis, and other conditions where substance P plays a role.
Questions still open
- Would combining NK1 receptor antagonists (which block substance P) with traditional anti-inflammatory drugs improve TBI outcomes in clinical trials?
- Can TRP channel inhibitors administered early after brain injury prevent the initiation of neurogenic inflammation?
- Does the neurogenic inflammatory feedback loop also drive chronic neurodegeneration after repeated mild traumatic brain injuries?
Common questions
What is substance P and what role does it play in brain injury?
Why have anti-inflammatory treatments for brain injury failed in clinical trials?
Read the original research
Neurogenic inflammation after traumatic brain injury and its potentiation of classical inflammation.
Journal of neuroinflammation, 13(1), 264
Citation
Corrigan, Frances; Mander, Kimberley A; Leonard, Anna V; Vink, Robert. (2016). Neurogenic inflammation after traumatic brain injury and its potentiation of classical inflammation.. Journal of neuroinflammation, 13(1), 264.